Alcon

Alcon is the global leader in eye care, boasting a heritage of over 75 years and a dominant presence in more than 140 countries. The company operates through two primary segments: Surgical and Vision Care. The Surgical segment offers a comprehensive portfolio of implantables, consumables, and advanced surgical equipment for cataracts, vitreoretinal diseases, and refractive errors. The Vision Care segment provides a wide array of contact lenses and ocular health products, including treatments for dry eye and ocular allergies. Since its spin-off from Novartis in 2019, Alcon has established itself as an independent powerhouse (NYSE/SIX: ALC), focusing heavily on R&D and strategic acquisitions. The company integrates digital health solutions like the MARLO patient platform with cutting-edge surgical robotics and pharmaceutical innovations. With approximately 25,000 employees worldwide, Alcon remains at the forefront of ophthalmic technology, recently expanding into cell therapy and advanced refractive solutions through high-value acquisitions.